These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease. Gryp T; De Paepe K; Vanholder R; Kerckhof FM; Van Biesen W; Van de Wiele T; Verbeke F; Speeckaert M; Joossens M; Couttenye MM; Vaneechoutte M; Glorieux G Kidney Int; 2020 Jun; 97(6):1230-1242. PubMed ID: 32317112 [TBL] [Abstract][Full Text] [Related]
24. Effect of prebiotic (fructooligosaccharide) on uremic toxins of chronic kidney disease patients: a randomized controlled trial. Ramos CI; Armani RG; Canziani MEF; Dalboni MA; Dolenga CJR; Nakao LS; Campbell KL; Cuppari L Nephrol Dial Transplant; 2019 Nov; 34(11):1876-1884. PubMed ID: 29939302 [TBL] [Abstract][Full Text] [Related]
25. Syndecan-1 and Free Indoxyl Sulfate Levels Are Associated with miR-126 in Chronic Kidney Disease. Fourdinier O; Glorieux G; Brigant B; Diouf M; Pletinck A; Vanholder R; Choukroun G; Verbeke F; Massy ZA; Metzinger-Le Meuth V; Metzinger L; Group-EUTox OBOTEUTW Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638892 [TBL] [Abstract][Full Text] [Related]
26. Role of Uremic Toxins for Kidney, Cardiovascular, and Bone Dysfunction. Fujii H; Goto S; Fukagawa M Toxins (Basel); 2018 May; 10(5):. PubMed ID: 29772660 [TBL] [Abstract][Full Text] [Related]
27. Chronic kidney disease (CKD) patients are exposed to more proton pump inhibitor (PPI)s compared to non-CKD patients. Lee HJ; Lee H; Oh SH; Park J; Park S; Jeon JS; Noh H; Han DC; Kwon SH PLoS One; 2018; 13(9):e0203878. PubMed ID: 30212538 [TBL] [Abstract][Full Text] [Related]
28. Assessment of uremic toxins in advanced chronic kidney disease patients on maintenance hemodialysis by LC-ESI-MS/MS. Ragi N; Pallerla P; Babi Reddy Gari AR; Lingampelly SS; Ketavarapu V; Addipilli R; Chirra N; Kantevari S; Yadla M; Sripadi P Metabolomics; 2023 Feb; 19(3):14. PubMed ID: 36826619 [TBL] [Abstract][Full Text] [Related]
29. Cognitive Function and Uremic Toxins after Kidney Transplantation: An Exploratory Study. Te Linde E; van Roij CJM; Meijers BKI; De Loor H; Kessels RPC; Wetzels JFM Kidney360; 2020 Dec; 1(12):1398-1406. PubMed ID: 35372897 [TBL] [Abstract][Full Text] [Related]
30. Dietary protein-fiber ratio associates with circulating levels of indoxyl sulfate and p-cresyl sulfate in chronic kidney disease patients. Rossi M; Johnson DW; Xu H; Carrero JJ; Pascoe E; French C; Campbell KL Nutr Metab Cardiovasc Dis; 2015 Sep; 25(9):860-865. PubMed ID: 26026209 [TBL] [Abstract][Full Text] [Related]
31. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. Lim CF; Bernard BF; de Jong M; Docter R; Krenning EP; Hennemann G J Clin Endocrinol Metab; 1993 Feb; 76(2):318-24. PubMed ID: 8432774 [TBL] [Abstract][Full Text] [Related]
32. Increased Levels of Total p-Cresylsulfate Are Associated with Pruritus in Patients with Chronic Kidney Disease. Wang CP; Lu YC; Tsai IT; Tang WH; Hsu CC; Hung WC; Yu TH; Chen SC; Chung FM; Lee YJ; Houng JY Dermatology; 2016; 232(3):363-70. PubMed ID: 27161100 [TBL] [Abstract][Full Text] [Related]
33. Proton pump inhibitor use and progression to major adverse renal events: a competing risk analysis. Grant CH; Gillis KA; Lees JS; Traynor JP; Mark PB; Stevens KI QJM; 2019 Nov; 112(11):835-840. PubMed ID: 31251364 [TBL] [Abstract][Full Text] [Related]
34. The quest for a better understanding of chronic kidney disease complications: an update on uremic toxins. Barreto FC; Stinghen AE; de Oliveira RB; Franco AT; Moreno AN; Barreto DV; Pecoits-Filho R; Drüeke TB; Massy ZA J Bras Nefrol; 2014; 36(2):221-35. PubMed ID: 25055363 [TBL] [Abstract][Full Text] [Related]
35. Protein-bound uremic toxins (PBUTs) in chronic kidney disease (CKD) patients: Production pathway, challenges and recent advances in renal PBUTs clearance. Daneshamouz S; Eduok U; Abdelrasoul A; Shoker A NanoImpact; 2021 Jan; 21():100299. PubMed ID: 35559786 [TBL] [Abstract][Full Text] [Related]
36. Diet Quality and Protein-Bound Uraemic Toxins: Investigation of Novel Risk Factors and the Role of Microbiome in Chronic Kidney Disease. McFarlane C; Krishnasamy R; Stanton T; Savill E; Snelson M; Mihala G; Morrison M; Johnson DW; Campbell KL J Ren Nutr; 2022 Sep; 32(5):542-551. PubMed ID: 34776340 [TBL] [Abstract][Full Text] [Related]
37. Study of the association between serum levels of kynurenine and cardiovascular outcomes and overall mortality in chronic kidney disease. El Chamieh C; Larabi IA; Alencar De Pinho N; Lambert O; Combe C; Fouque D; Frimat L; Jacquelinet C; Laville M; Laville S; Lange C; Alvarez JC; Massy ZA; Liabeuf S; Clin Kidney J; 2024 Jan; 17(1):sfad248. PubMed ID: 38186868 [TBL] [Abstract][Full Text] [Related]
38. AST-120 to Target Protein-Bound Uremic Toxins Improves Cardiac Output and Kidney Oxygenation in Experimental Chronic Kidney Disease. Sivertsson E; Ceder S; Nangaku M; Hansell P; Nordquist L; Palm F Kidney Blood Press Res; 2023; 48(1):114-123. PubMed ID: 36791683 [TBL] [Abstract][Full Text] [Related]
39. Is there an association between the plasma levels of uremic toxins from gut microbiota and anemia in patients on hemodialysis? Capo-Chichi JCC; Borges NA; de Vargas Reis DCM; Nakao LS; Mafra D Int Urol Nephrol; 2022 Jun; 54(6):1271-1277. PubMed ID: 34561817 [TBL] [Abstract][Full Text] [Related]